We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TFX or STE: Which is a Better Investment Pick Right Now?
Read MoreHide Full Article
Medical Instrument companies Teleflex Incorporated (TFX - Free Report) and STERIS plc (STE - Free Report) are two solid contenders in the U.S. surgical instruments space, which is expected to reach a worth of $11.28 billion by the end of 2019, per Transparency Market Research.
OH-based STERIS, in process of providing infection prevention, and other procedural products and services, largely specializes in the manufacture of surgical and sterile processing equipment.
A huge portion of PA-based Teleflex’s portfolio comprises a range of minimally invasive surgical products, including MiniLap Percutaneous Surgical System, Weck Hem-o-lok Polymer Locking Ligation System, and Weck EFx Shield Fascial Closure System.
Here, we make a detailed analysis of the companies’ fundamentals to determine which has a slight edge over the other.
Price Performance
In the past year, Teleflex’s shares have gained 20.8% compared with STERIS’ rally of 36.3%. The Medical Instruments industry has gained 2.5% during the same time frame.
This demonstrates STERIS to be the more favorable stock.
Which Way Are Estimates Headed?
Earnings
The Zacks Consensus Estimate for Teleflex’s current-year earnings stands at $11.05, implying an improvement of 11.6% from the figure reported in the previous year. The same for STERIS is projected at $5.37, indicating rise of 9.8% from the prior-year reported figure.
Sales
The Zacks Consensus Estimate for Teleflex’s current-year revenues is pegged at $2.59 billion, suggesting growth of 5.6% from the figure reported in the previous year. The same for STERIS is pegged at $2.94 billion, calling for rise of 5.6% from the prior-year reported figure.
Clearly, Teleflex has a competitive advantage over STERIS, with respect to current-year earnings estimates.
How Does Valuation Look?
Teleflex stock currently looks overvalued when compared with STERIS. Teleflex currently trades at a price-to-sales ratio (TTM basis) of 6.37 compared with STERIS’s 4.61. Meanwhile, the industry’s ratio stands at 3.43.
Hence, STERIS wins this round.
Recent Financial Results
Teleflex
For the first quarter of 2019, Teleflex reported earnings per share (EPS) from continuing operations of $2.24, up 4.2% year over year. The bottom line also surpassed the Zacks Consensus Estimate by 3.7%.
Net revenues from continuing operations in the first quarter rose 4.5% year over year to $613.6 million. On a year-over-year basis, the company saw organic constant-currency revenue growth of 7.6%. The top line surpassed the Zacks Consensus Estimate by 0.9%
STERIS
STERIS reported fourth-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.53, up 23.4% year over year. The metric surpassed the Zacks Consensus Estimate by 6.3%.
Revenues of $768.2 million in the quarter rose 7.3% year over year and surpassed the Zacks Consensus Estimate by 4.6%.
Factors Driving Growth
Teleflex
NeoTract, the acquired business of Teleflex, has already begun contributing to the its top line significantly. In the last reported quarter, NeoTract continued building strong momentum and as a result, Interventional Urology business registered 45% year-over-year growth.The synergies from the acquisition of Vascular Solutions have been contributing to Teleflex’s top line since the last reported quarter. In the first quarter, revenues from Vascular Solutions registered 2.5% rise from the prior-year period, owing to strength in PICC (Peripherally Inserted Central Catheters) and visual navigation products.
The company has reaffirmed its revenue and EPS guidance for 2019.
STERIS
The acquisition of U.K.-based outsourced sterilization services provider Synergy Healthhas boosted STERIS’ presence in the international markets by combining the strong presence of the latter in North America with Synergy’s solid footprint across Europe. Synergy has also provided the company an opportunity to better serve the emerging markets of the Asia Pacific and Latin America.
High potential in healthcare and pharmaceutical industries, driven by the aging of the global population and an increasing number of individuals entering their prime healthcare consumption years, has also been expanding the company’s foothold in the market lately.
Management anticipates constant-currency organic revenue growth of 5-6%, with currency impact approximately neutral to its revenue guidance.
To Wrap it Up
Our comparative analysis indicates that STERIS is better-positioned than Teleflex, considering price performance and valuation. However, Teleflex has an edge on the basis of current-year earnings estimates.
In terms of both companies’ growth prospects, investors are hopeful about STERIS’ acquisition of Synergy Health and Teleflex being benefited from the Vascular Solutions acquisition.
Other Key Picks
A couple of other top-ranked stocks in the broader medical space are NuVasive and Penumbra (PEN - Free Report) . While Penumbra currently sports a Zacks Rank #1, NuVasive carries a Zacks Rank #2.
NuVasive’s long-term earnings growth rate is expected to be 11.9%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
TFX or STE: Which is a Better Investment Pick Right Now?
Medical Instrument companies Teleflex Incorporated (TFX - Free Report) and STERIS plc (STE - Free Report) are two solid contenders in the U.S. surgical instruments space, which is expected to reach a worth of $11.28 billion by the end of 2019, per Transparency Market Research.
OH-based STERIS, in process of providing infection prevention, and other procedural products and services, largely specializes in the manufacture of surgical and sterile processing equipment.
A huge portion of PA-based Teleflex’s portfolio comprises a range of minimally invasive surgical products, including MiniLap Percutaneous Surgical System, Weck Hem-o-lok Polymer Locking Ligation System, and Weck EFx Shield Fascial Closure System.
Notably both companies carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Here, we make a detailed analysis of the companies’ fundamentals to determine which has a slight edge over the other.
Price Performance
In the past year, Teleflex’s shares have gained 20.8% compared with STERIS’ rally of 36.3%. The Medical Instruments industry has gained 2.5% during the same time frame.
This demonstrates STERIS to be the more favorable stock.
Which Way Are Estimates Headed?
Earnings
The Zacks Consensus Estimate for Teleflex’s current-year earnings stands at $11.05, implying an improvement of 11.6% from the figure reported in the previous year. The same for STERIS is projected at $5.37, indicating rise of 9.8% from the prior-year reported figure.
Sales
The Zacks Consensus Estimate for Teleflex’s current-year revenues is pegged at $2.59 billion, suggesting growth of 5.6% from the figure reported in the previous year. The same for STERIS is pegged at $2.94 billion, calling for rise of 5.6% from the prior-year reported figure.
Clearly, Teleflex has a competitive advantage over STERIS, with respect to current-year earnings estimates.
How Does Valuation Look?
Teleflex stock currently looks overvalued when compared with STERIS. Teleflex currently trades at a price-to-sales ratio (TTM basis) of 6.37 compared with STERIS’s 4.61. Meanwhile, the industry’s ratio stands at 3.43.
Hence, STERIS wins this round.
Recent Financial Results
Teleflex
For the first quarter of 2019, Teleflex reported earnings per share (EPS) from continuing operations of $2.24, up 4.2% year over year. The bottom line also surpassed the Zacks Consensus Estimate by 3.7%.
Net revenues from continuing operations in the first quarter rose 4.5% year over year to $613.6 million. On a year-over-year basis, the company saw organic constant-currency revenue growth of 7.6%. The top line surpassed the Zacks Consensus Estimate by 0.9%
STERIS
STERIS reported fourth-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.53, up 23.4% year over year. The metric surpassed the Zacks Consensus Estimate by 6.3%.
Revenues of $768.2 million in the quarter rose 7.3% year over year and surpassed the Zacks Consensus Estimate by 4.6%.
Factors Driving Growth
Teleflex
NeoTract, the acquired business of Teleflex, has already begun contributing to the its top line significantly. In the last reported quarter, NeoTract continued building strong momentum and as a result, Interventional Urology business registered 45% year-over-year growth.The synergies from the acquisition of Vascular Solutions have been contributing to Teleflex’s top line since the last reported quarter. In the first quarter, revenues from Vascular Solutions registered 2.5% rise from the prior-year period, owing to strength in PICC (Peripherally Inserted Central Catheters) and visual navigation products.
The company has reaffirmed its revenue and EPS guidance for 2019.
STERIS
The acquisition of U.K.-based outsourced sterilization services provider Synergy Healthhas boosted STERIS’ presence in the international markets by combining the strong presence of the latter in North America with Synergy’s solid footprint across Europe. Synergy has also provided the company an opportunity to better serve the emerging markets of the Asia Pacific and Latin America.
High potential in healthcare and pharmaceutical industries, driven by the aging of the global population and an increasing number of individuals entering their prime healthcare consumption years, has also been expanding the company’s foothold in the market lately.
Management anticipates constant-currency organic revenue growth of 5-6%, with currency impact approximately neutral to its revenue guidance.
To Wrap it Up
Our comparative analysis indicates that STERIS is better-positioned than Teleflex, considering price performance and valuation. However, Teleflex has an edge on the basis of current-year earnings estimates.
In terms of both companies’ growth prospects, investors are hopeful about STERIS’ acquisition of Synergy Health and Teleflex being benefited from the Vascular Solutions acquisition.
Other Key Picks
A couple of other top-ranked stocks in the broader medical space are NuVasive and Penumbra (PEN - Free Report) . While Penumbra currently sports a Zacks Rank #1, NuVasive carries a Zacks Rank #2.
NuVasive’s long-term earnings growth rate is expected to be 11.9%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>